John Samson Bimba

Dr. John Samson Bimba

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PCPatricia Comella-del-Barrio
Patricia Comella-del-Barrio
JBJohn Samson Bimba
John Samson Bimba
RARamota Adelakun
Ramota Adelakun
KKKonstantina Kontogianni
Konstantina Kontogianni
BMBarbara Molina-Moya
Barbara Molina-Moya
JDJose Dominguez
Jose Dominguez
There is a need for diagnostics for tuberculosis (TB) that are easy to use, able to screen non-sputum samples, and able to provide rapid results for the management of both immunocompromised and immunocompetent individuals. The Fujifilm SILVAMP TB LAM (FujiLAM) assay, a new non-sputum based point of need test for the diagnosis of TB, could potentially address most of these needs. We evaluated the performance of FujiLAM in HIV positive and HIV negative patients with presumptive TB attending three district hospitals in Nigeria. Consecutive patients were asked to provide urine samples on the spot, which were tested with FujiLAM. The results were compared against a positive culture and/or Xpert MTB/RIF as the reference standard. Forty-five patients had bacteriologically confirmed TB, and 159 had negative culture and Xpert MTB/RIF (no TB). The FujiLAM test was positive in 23 (sensitivity 65.7%, 95% CI = 48–80) HIV negative and seven (70%, 95% CI = 35–92) HIV positive patients with bacteriological confirmation of TB. FujiLAM was negative in 97 (specificity 99.0%, 95% CI = 94–100) HIV negative and 56 (93.3%, 95% CI = 83–98) HIV positive patients without TB. The FujiLAM test has good diagnostic accuracy for considering its application in both HIV positive and HIV negative patients with TB.

1 August 2017 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
LLLovett Lawson
Lovett Lawson
MMMagdalena Muc
Magdalena Muc
OOOlanrewaju Oladimeji
Olanrewaju Oladimeji
CIChijioke Iweha
Chijioke Iweha
BOBlessing Opoola
Blessing Opoola
LCLuis Cuevas
Luis Cuevas
Type 2 diabetes mellitus (DM) and HIV increase the risk of tuberculosis (TB). The frequency of DM among patients with TB with and without HIV is poorly documented in many low- and middle-income countries. This was a cross-sectional hospital-based study performed in Abuja, Nigeria. Adults with presumptive TB were screened consecutively. Sputum culture was used for TB screening and blood was used for HIV screening, as well as fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) assessment for the diagnosis of DM. HbA1c was measured using the D-10 Haemoglobin Testing System and a point-of-care test (A1C Now+ system) for comparison. Patients were classified as having DM or pre-diabetes using the D-10 reference test. Four hundred and ten individuals had TB culture, FPG, and HbA1c results. Participants had a mean (±standard deviation) age of 37.8±12.6 years and 217 (54.8%) were male. One hundred and thirteen (27.6%) patients were culture-positive, 62 (15.1%) had DM, and 46 (11.2%) had pre-diabetes. One hundred and eighty-four (53.3%) participants were HIV-positive and 95 (51.6%) were on antiretroviral therapy (ART). Patients with pre-diabetes and DM were more likely to have TB (odds ratio (OR) 1.94, 95% confidence interval (CI) 0.01-3.74, and OR 2.39, 95% CI 1.35-4.24, respectively). After adjustment for HIV, age, and sex, only DM was statistically associated with TB (adjusted OR (AOR) 3.10, 95% CI 1.62-5.94). HIV-negative patients with DM had a higher risk of TB (AOR 4.32, 95% CI 1.57-11.92) than HIV-positive patients with DM (AOR 3.31, 95% CI 1.29-8.54), but the difference was not statistically significant. A1C Now+ HbA1c measurements correlated poorly with the D-10 HbA1c reference test. A high proportion of patients in Abuja have markers of DM and pre-diabetes at the time of TB diagnosis.

4 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JBJohn Samson Bimba
John Samson Bimba
LLLovett Lawson
Lovett Lawson
KKKonstantina Kontogianni
Konstantina Kontogianni
TEThomas Edwards
Thomas Edwards
BEBASSEY EMMANA EKPENYONG
BASSEY EMMANA EKPENYONG
LCLuis Cuevas
Luis Cuevas
Background: Xpert MTB/RIF (GX) for tuberculosis (TB) diagnosis is often located in reference laboratories, and sputum needs to be transported using a cold chain. Transport media to preserve sputum are available, but performance data under programmatic conditions are limited. Methods: Sputum samples were collected from patients with presumptive TB in Nigeria. One sputum was transported in a cold chain, tested immediately with GX and cultured. One sputum was swabbed and stored in PrimeStore-Molecular-Transport-Medium (Primestore), and the remainder was stored in OMNIGene-sputum (Omnigene), kept for seven days and tested with GX. Results: Of 248 patients, 63 were fresh-sputum culture-positive and 56 GX-positive (sensitivity 88.9%, 95% CI: 78.4–95.4%). Four of 185 culture-negative patients were GX-positive (specificity 97.8%, 94.6–99.4%). Omnigene GX and Primestore GX were positive in 56/62 (90.3%, 80.1–96.4%) and 49/62 (79.0%, 66.8–88.3%) culture-positive, respectively, and 1/185 (99.5%, 97.0–100.0%) and 3/185 (98.4%, 95.3–99.7%) were culture-negative patients. 14 Human Immunodeficiency Virus (HIV)-infected and 44 HIV-uninfected patients were culture-positive. Omnigene and Primestore detected 12/14 (85.7%, 57.2–98.2%) and 5/14 (35.7%, 12.8–64.9%) HIV-infected and 41/44 (93.2%, 81.3–98.6%) HIV-uninfected culture-positive patients. Interpretation: Omnigene stored and fresh sputum samples had similar GX results. The GX results of Primestore-stored samples were similar to those found in the fresh sputum of non-HIV infected patients, but GX-positivity was lower in HIV-infected patients. This was likely due to the lower amount of bacilli collected by the swab and transferred to PrimeStore.

1 October 2018 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
BMBarbara Molina-Moya
Barbara Molina-Moya
SASaddiq T Abdurrahman
Saddiq T Abdurrahman
LMLaura I Madukaji
Laura I Madukaji
MGMichel Kiréopori Gomgnimbou
Michel Kiréopori Gomgnimbou
LSLizania Spinasse
Lizania Spinasse
JDJose Dominguez
Jose Dominguez
Objective: Nigeria ranks fourth among the high tuberculosis (TB) burden countries. This study describes the prevalence of drug resistance and the genetic diversity of Mycobacterium tuberculosis in Abuja’s Federal Capital Territory. Materials and methods: Two hundred and seventy-eight consecutive sputum samples were collected from adults with presumptive TB during 2013–2014. DNA was extracted from Löwenstein–Jensen cultures and analyzed for the identification of nontuberculous mycobacteria species, detection of drug resistance with line probe assays, and high-throughput spacer oligonucleotide typing (spoligotyping) using microbead-based hybridization. Results: Two hundred and two cultures were positive for M. tuberculosis complex, 24 negative, 38 contaminated, and 15 positive for nontuberculous mycobacteria. Five (2.5%) M. tuberculosis complex isolates were resistant to rifampicin (RIF) and isoniazid (multidrug resistant), nine (4.5%) to RIF alone, and 15 (7.4%) to isoniazid alone; two RIF-resistant isolates were also resistant to fluoroquinolones and ethambutol, and one multidrug resistant isolate was also resistant to ethambutol. Among the 180 isolates with spoligotyping results, 164 (91.1%) were classified as lineage 4 (Euro-American), 13 (7.2%) as lineage 5 (West African 1), two (1.1%) as lineage 2 (East Asia), and one (0.6%) as lineage 6 (West African 2). One hundred and fifty-six (86.7%) isolates were grouped in 17 clusters (2–108 isolates/cluster), of which 108 (60.0%) were grouped as L4.6.2/Cameroon (spoligotype international type 61). Conclusion: The description of drug resistance prevalence and genetic diversity of M. tuberculosis in this study may be useful for improving TB control in Nigeria.

1 March 2023 in Public Health Action
Verified
Journal Article
Closed access
JBJohn Samson Bimba
John Samson Bimba
OAO. A. Adekeye
O. A. Adekeye
VIV. Iem
V. Iem
TET. T. Eliya
T. T. Eliya
IOI. Osagie
I. Osagie
LCL. E. Cuevas
L. E. Cuevas
BACKGROUND: The use of molecular amplification as-says for TB diagnosis is limited by their costs and cartridge stocks. Pooling multiple samples to test them together is reported to have similar accuracy to individual testing and to save costs. METHODS: Two surveys of individuals with presumptive TB were conducted to assess the performance of pooled testing using Xpert® MTB/RIF (MTB/RIF) and Xpert® Ultra (Ultra). RESULTS: A total of 500 individuals were tested using MTB/RIF, with 72 (14.4%) being MTB-positive. The samples were tested in 125 pools, with 50 pools having 1 MTB-positive and 75 only MTB-negative samples: 46/50 (92%, 95% CI 80.8–97.8) MTB-positive pools tested MTB-positive and 71/75 (94.7%, 95% CI 86.9–98.5) MTB-negative pools tested MTB-negative in the pooled test (agreement: 93.6%, κ = 0.867). Five hundred additional samples were tested using Ultra, with 60 (12%) being MTB-positive. Samples were tested in 125 pools, with 42 having 1 MTB-positive and 83 only MTB-negative samples: 35/42 (83.6%, 95% CI 68.6–93.0) MTB-positive pools tested MTB-positive and 82/83 (98.8%, 95% CI 93.5–100.0) MTB-negative pools tested MTB-negative in the pooled test (agreement: 93.6%, κ = 0.851; P > 0.1 between individual and pooled testing). Pooled testing saved 35% (MTB/RIF) and 46% (Ultra) of cartridges. CONCLUSIONS: Pooled and individual testing has a high level of agreement and improves testing efficiency.

2 April 2025 in medRxiv
Verified
Preprint
Open access
ARAlexandra S Richards
Alexandra S Richards
MPMphatso D Phiri
Mphatso D Phiri
JNJasper Nidoi
Jasper Nidoi
JCJeremiah Chakaya
Jeremiah Chakaya
PMPeter MacPherson
Peter MacPherson
KHKatherine C Horton
Katherine C Horton
Background: Globally, the burden of tuberculosis (TB) falls more on men than women and children, and there are large gaps between men and women at all stages of exposure, disease incidence, and treatment. We examined the impact of addressing determinants of these gender gaps in Kenya, Malawi, Nigeria, and Uganda. Methods and Findings: We created a deterministic transmission model of TB, with strata for sex, age, and HIV co-infection and antiretroviral therapy, and calibrated to country-specific data on prevalence, incidence, mortality, and notifications between 2010 and 2022. We then examined the potential epidemiological impact of strategies to increase treatment coverage among men, and decrease the effects of social and structural determinants that increase men’s risk of developing TB. We investigated impact (overall and by age and sex) on projected incidence and mortality in 2035, and notification rates between 2025 and 2030. Relative reductions in overall TB incidence from increased treatment coverage among men ranged from 4.8% [95% uncertainty interval (UI)0.7-10.6%] in Malawi to 24.8% [UI 14.3-37.0%] in Uganda. Reducing men’s excess risk of TB led to a similar range in relative reductions from 8.4% [UI 6.6-10.4%] in Nigeria to 23.3% [UI 18.0-30.0%] in Uganda. Combining strategies increased the relative reduction beyond that seen with one strategy alone, but as would be anticipated by greater prevention of incident TB, less than the sum of both strategies. Impacts extended across the population with median estimates of country-level declines in incidence of between 1.6—10.6% and 2.8—19.5% in women and children respectively, across the four countries. Increasing treatment coverage increased the median country-level estimates of notifications between 3.1% and 12.4% in the first three years, however combining increased treatment coverage with a reduction in risk reduced the median annual country-level notifications by 6.7% to 18.1% by 2035. Conclusion: Strategies that prioritise increasing TB treatment coverage among men and mitigating men’s higher susceptibility to TB could reduce disease burden for men, women, and children. Such gender-responsive strategies are essential to ensure a person-centred TB response and accelerate global progress towards the End TB targets.